Dren Bio

San Carlos, United States Founded: 2019 • Age: 7 yrs
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
Request Access

About Dren Bio

Dren Bio is a company based in San Carlos (United States) founded in 2019 by John Wesley and Nenad Tomasevic.. Dren Bio has raised $131 million across 3 funding rounds from investors including Pfizer, ARE and Revelation Partners. Dren Bio operates in a competitive market with competitors including Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others.

  • Headquarter San Carlos, United States
  • Founders John Wesley, Nenad Tomasevic
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Pharmaceuticals & Therapeutics
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $131 M (USD)

    in 3 rounds

  • Latest Funding Round
    $65 M (USD), Series B

    Mar 28, 2022

  • Investors
    Pfizer

    & 10 more

  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Dren Bio
Headcount 10-50
Employee Profiles 20
Board Members and Advisors 6
Employee Profiles
People
Jeff Macfarland
SVP, Finance
People
Nenad Tomasevic
Founder, President & CEO
People
Solomon Quezada
Facilities Manager
People
Teodora Losic
Business Development Manager

Unlock access to complete

Board Members and Advisors
people
Rajeev Dadoo
Director
people
Sakae Asanuma
Director
people
Stefano Ricagno
Scientific Advisor
people
Alex Kolicich
Director

Unlock access to complete

Funding Insights of Dren Bio

Dren Bio has successfully raised a total of $131M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $65 million completed in March 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series B — $65.0M
  • First Round

    (01 Jun 2019)

  • Investors Count 11
Date Amount Transaction Name Valuation Lead Investors Investors
Mar, 2022 Amount Series B - Dren Bio Valuation Aisling Capital , HBM Healthcare Investments
Sep, 2020 Amount Series A - Dren Bio Valuation SR One , Taiho Ventures
Jun, 2019 Amount Seed - Dren Bio Valuation 8VC
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Dren Bio

Dren Bio has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, ARE and Revelation Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
PE firm investing in the US
Founded Year Domain Location
Life sciences focused VC firm funding companies in the US and Europe
Founded Year Domain Location
A biotechnology venture capital firm investing in innovative science.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Dren Bio

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Dren Bio

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Dren Bio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Dren Bio

Dren Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Horizon Therapeutics, Forge Biologics, argenx and Annexon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
mRNA-based therapeutics for diseases including cancer and infections are developed.
domain founded_year HQ Location
Developer of drugs for treating rare and autoimmune diseases
domain founded_year HQ Location
Gene therapies for rare diseases are developed to treat patients.
domain founded_year HQ Location
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
domain founded_year HQ Location
Developer of antibodies to treat complement-mediated neurodegenerative diseases
domain founded_year HQ Location
Therapeutics for autoimmune diseases are developed by the company.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Dren Bio

Frequently Asked Questions about Dren Bio

When was Dren Bio founded?

Dren Bio was founded in 2019.

Where is Dren Bio located?

Dren Bio is headquartered in San Carlos, United States. It is registered at San Carlos, California, United States.

Who is the current CEO of Dren Bio?

Nenad Tomasevic is the current CEO of Dren Bio. They have also founded this company.

Is Dren Bio a funded company?

Dren Bio is a funded company, having raised a total of $131M across 3 funding rounds to date. The company's 1st funding round was a Seed of $6M, raised on Jun 01, 2019.

What does Dren Bio do?

Dren Bio was founded in 2019 and is headquartered in San Carlos, United States. Antibodies are developed for treating cancer, autoimmune conditions, and other serious diseases within the biotechnology sector. Operations focus on candidates like DR-01, a nonfucosylated antibody for hematologic malignancies, and DR-0201, a targeted myeloid engager using a phagocytosis platform for B cell malignancies.

Who are the top competitors of Dren Bio?

Dren Bio's top competitors include Moderna, argenx and Forge Biologics.

Who are Dren Bio's investors?

Dren Bio has 11 investors. Key investors include Pfizer, ARE, Revelation Partners, HBM Healthcare Investments, and ArrowMark Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available